Verapamil and biodegradeable polymer product

Calosyn Pharma is at the forefront of developing innovative treatments for osteoarthritis, particularly through its lead product, CAL-05CR. This novel, long-acting injectable therapy combines verapamil with a biodegradable polymer to provide sustained-release pain relief directly at the site of inflammation. Unlike traditional treatments that primarily address symptoms, CAL-05CR targets the underlying causes of osteoarthritis by regulating calcium ion channels, which play a significant role in the degenerative processes of the condition. This mechanism not only reduces inflammation but also helps preserve cartilage, offering a dual benefit of pain relief and joint health.

The sustained-release technology embedded in microspheres allows CAL-05CR to deliver therapeutic concentrations over an extended period, significantly reducing the need for frequent injections. This innovative approach minimizes side effects typically associated with systemic treatments, making it a more patient-friendly option. With extensive pre-clinical and clinical studies backing its efficacy, CAL-05CR is positioned as a breakthrough in osteoarthritis management, aiming to improve the quality of life for millions affected by this degenerative disease. Calosyn Pharma's commitment to advancing osteoarthritis therapies underscores its mission to provide lasting solutions for patients.

United States

Calosyn has developed intra-articular therapeutic drugs for osteoarthritis of the knee based on proprietary combinations of ion channel modulators (ICM’s) currently in clinical use.

Calosyn Pharma

Company Details